Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


StemCells Inc. To Wind Down Operations After Phase II Failure

Executive Summary

StemCells Inc. plunged 81.2% to $0.57 per share on May 31 after the company revealed little chance of success for a Phase II spinal cord injury study, which has been terminated, and said that it may not be able to return any cash to shareholders after StemCells winds down its operations this year.


Related Content

Stem Cell Data Boosts Asterias In Untapped Spinal Injury Space
IPO Update: Protagonist, Gemphire, Kadmon Launches Fall Flat
StemCells names president & COO
BioNotebook: Controversial StemCells board appointment; Portola/Daiichi Sankyo, Lexicon/JDRF, Supernus; and stock offerings
StemCells raises cash, brings spinal cord injury study to US
Second $20m loan for StemCells Inc alongside Capricor's first under California stem cell programme


Related Companies

Related Deals

What to read next




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts